therapeutic window


Also found in: Wikipedia.
A well-defined range of a drug’s serum concentration at which a desired effect occurs, below which there is little effect, and above which toxicity occurs; the window differs among patients and may be determined empirically

therapeutic window

The well-defined range of a drug's serum concentration at which a desired effect occurs, below which there is little effect, above which toxicity occurs; the TW differs among Pts and may be determined empirically. See Therapeutic drug monitoring. Cf Window.
References in periodicals archive ?
ADCs incorporating ZymeLink have demonstrated a greater therapeutic window in preclinical testing than those incorporating the commonly used ADC payloads DM1 or MMAE.
Iii) to test in a preclinical mouse model of ia efficient anti-platelet therapies and define a therapeutic window to intervene on platelet activation.
SHR0302, a highly potent, selective JAK inhibitor designed to offer a greater therapeutic window through high selectivity, high potency, and an extended tissue half-life, is currently being evaluated in Phase 2 clinical trials for rheumatoid arthritis in China.
Fentanyl is a powerful pain killer, but one with a narrow therapeutic window and a history of overdoses.
Compared to 1st-generation, BI 882370 may provide an improved therapeutic window, enabling more pronounced and longer-lasting pathway suppression and thus resulting in improved efficacy.
Our findings also indicate that the potential therapeutic window for effective MSCbFGF use is approximately one to two weeks," she added.
The key is to keep the levels within the therapeutic window.
This therapeutic window likely applies to most patients; however, patient-specific variables could alter the optimum dosage.
Targeting IL-23 alone may allow for a broader therapeutic window versus IL12/23 targeting therapies and may translate into better efficacy.
The structure design of its first derivative, anti-CD3 Collabody is meant to resolve the narrow therapeutic window of the existing anti-human CD3 antibody products--teplizumab and otelixizumab, both of which were failed in clinical phase 3 trails in treating patients with type 1 diabetes mellitus disease.
Our study suggests a potential therapeutic window of opportunity, in a period that correlates with mid-life in zebrafish, before age-associated defects become apparent.
The therapeutic window of erlotinib is narrow, and the recommended dosage is close to the maximum tolerable dosage.